262 related articles for article (PubMed ID: 24018261)
1. Comprehensive identification of mutations responsible for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA)-to-VISA conversion in laboratory-generated VISA strains derived from hVISA clinical strain Mu3.
Matsuo M; Cui L; Kim J; Hiramatsu K
Antimicrob Agents Chemother; 2013 Dec; 57(12):5843-53. PubMed ID: 24018261
[TBL] [Abstract][Full Text] [Related]
2. "Slow VISA," a novel phenotype of vancomycin resistance, found in vitro in heterogeneous vancomycin-intermediate Staphylococcus aureus strain Mu3.
Saito M; Katayama Y; Hishinuma T; Iwamoto A; Aiba Y; Kuwahara-Arai K; Cui L; Matsuo M; Aritaka N; Hiramatsu K
Antimicrob Agents Chemother; 2014 Sep; 58(9):5024-35. PubMed ID: 24841271
[TBL] [Abstract][Full Text] [Related]
3. Mutation of RNA polymerase beta subunit (rpoB) promotes hVISA-to-VISA phenotypic conversion of strain Mu3.
Matsuo M; Hishinuma T; Katayama Y; Cui L; Kapi M; Hiramatsu K
Antimicrob Agents Chemother; 2011 Sep; 55(9):4188-95. PubMed ID: 21746940
[TBL] [Abstract][Full Text] [Related]
4. A mutation of RNA polymerase β' subunit (RpoC) converts heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA) into "slow VISA".
Matsuo M; Hishinuma T; Katayama Y; Hiramatsu K
Antimicrob Agents Chemother; 2015 Jul; 59(7):4215-25. PubMed ID: 25941225
[TBL] [Abstract][Full Text] [Related]
5. Complete Reconstitution of the Vancomycin-Intermediate Staphylococcus aureus Phenotype of Strain Mu50 in Vancomycin-Susceptible S. aureus.
Katayama Y; Sekine M; Hishinuma T; Aiba Y; Hiramatsu K
Antimicrob Agents Chemother; 2016 Jun; 60(6):3730-42. PubMed ID: 27067329
[TBL] [Abstract][Full Text] [Related]
6. Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem.
Katayama Y; Murakami-Kuroda H; Cui L; Hiramatsu K
Antimicrob Agents Chemother; 2009 Aug; 53(8):3190-6. PubMed ID: 19451283
[TBL] [Abstract][Full Text] [Related]
7. Modulating activity of vancomycin and daptomycin on the expression of autolysis cell-wall turnover and membrane charge genes in hVISA and VISA strains.
Cafiso V; Bertuccio T; Spina D; Purrello S; Campanile F; Di Pietro C; Purrello M; Stefani S
PLoS One; 2012; 7(1):e29573. PubMed ID: 22253738
[TBL] [Abstract][Full Text] [Related]
8. Different Vancomycin-Intermediate Staphylococcus aureus Phenotypes Selected from the Same ST100-hVISA Parental Strain.
Di Gregorio S; Fernandez S; Cuirolo A; Verlaine O; Amoroso A; Mengin-Lecreulx D; Famiglietti A; Joris B; Mollerach M
Microb Drug Resist; 2017 Jan; 23(1):44-50. PubMed ID: 27991847
[TBL] [Abstract][Full Text] [Related]
9. Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia.
Howden BP; Smith DJ; Mansell A; Johnson PD; Ward PB; Stinear TP; Davies JK
BMC Microbiol; 2008 Feb; 8():39. PubMed ID: 18304359
[TBL] [Abstract][Full Text] [Related]
10. Contribution of selected gene mutations to resistance in clinical isolates of vancomycin-intermediate Staphylococcus aureus.
Hafer C; Lin Y; Kornblum J; Lowy FD; Uhlemann AC
Antimicrob Agents Chemother; 2012 Nov; 56(11):5845-51. PubMed ID: 22948864
[TBL] [Abstract][Full Text] [Related]
11. walK and clpP mutations confer reduced vancomycin susceptibility in Staphylococcus aureus.
Shoji M; Cui L; Iizuka R; Komoto A; Neoh HM; Watanabe Y; Hishinuma T; Hiramatsu K
Antimicrob Agents Chemother; 2011 Aug; 55(8):3870-81. PubMed ID: 21628539
[TBL] [Abstract][Full Text] [Related]
12. Reduced susceptibility to vancomycin in isogenic Staphylococcus aureus strains of sequence type 59: tracking evolution and identifying mutations by whole-genome sequencing.
Chen CJ; Lin MH; Shu JC; Lu JJ
J Antimicrob Chemother; 2014 Feb; 69(2):349-54. PubMed ID: 24092658
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of Slow-Growth Vancomycin Nonsusceptibility in Methicillin-Resistant Staphylococcus aureus.
Katayama Y; Azechi T; Miyazaki M; Takata T; Sekine M; Matsui H; Hanaki H; Yahara K; Sasano H; Asakura K; Takaku T; Ochiai T; Komatsu N; Chambers HF
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28827421
[TBL] [Abstract][Full Text] [Related]
14. Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance.
Neoh HM; Cui L; Yuzawa H; Takeuchi F; Matsuo M; Hiramatsu K
Antimicrob Agents Chemother; 2008 Jan; 52(1):45-53. PubMed ID: 17954695
[TBL] [Abstract][Full Text] [Related]
15. The evolution of vancomycin intermediate Staphylococcus aureus (VISA) and heterogenous-VISA.
Howden BP; Peleg AY; Stinear TP
Infect Genet Evol; 2014 Jan; 21():575-82. PubMed ID: 23567819
[TBL] [Abstract][Full Text] [Related]
16. VraR Binding to the Promoter Region of
Dai Y; Chang W; Zhao C; Peng J; Xu L; Lu H; Zhou S; Ma X
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28289032
[TBL] [Abstract][Full Text] [Related]
17. Impact of mutations in hVISA isolates on decreased susceptibility to vancomycin, through population analyses profile - area under curve (PAP-AUC).
Silveira ACO; Caierão J; Silva CI; Anzai EK; McCulloch JA; d'Azevedo PA; Sincero TCM
Diagn Microbiol Infect Dis; 2019 Nov; 95(3):114854. PubMed ID: 31366440
[TBL] [Abstract][Full Text] [Related]
18. Systematic Review and Meta-Analysis of the Epidemiology of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates.
Zhang S; Sun X; Chang W; Dai Y; Ma X
PLoS One; 2015; 10(8):e0136082. PubMed ID: 26287490
[TBL] [Abstract][Full Text] [Related]
19. High prevalence of a globally disseminated hypervirulent clone, Staphylococcus aureus CC121, with reduced vancomycin susceptibility in community settings in China.
Shen P; Zhou K; Wang Y; Song J; Liu Y; Zhou Y; Xiao Y
J Antimicrob Chemother; 2019 Sep; 74(9):2537-2543. PubMed ID: 31203362
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA) emerged before the clinical introduction of vancomycin in Japan: a retrospective study.
Yamakawa J; Aminaka M; Okuzumi K; Kobayashi H; Katayama Y; Kondo S; Nakamura A; Oguri T; Hori S; Cui L; Ito T; Jin J; Kurosawa H; Kaneko K; Hiramatsu K
J Infect Chemother; 2012 Jun; 18(3):406-9. PubMed ID: 22033576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
